Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations
US-2015376230-A1 · Dec 31, 2015 · US
Detecting and treating breast cancer resistance to EGFR inhibitors
US9303088B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9303088-B2 |
| Application number | US-201113248690-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 29, 2011 |
| Priority date | Apr 1, 2009 |
| Publication date | Apr 5, 2016 |
| Grant date | Apr 5, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The application describes therapeutic compositions and methods for treating cancer. For example, therapeutic compositions and methods related to inhibition of FAM83A (family with sequence similarity 83) are provided. The application also describes methods for diagnosing cancer resistance to EGFR inhibitors. For example, a method of diagnosing cancer resistance to EGFR inhibitors by detecting increased FAM83A levels is described.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of predicting a clinical outcome for a patient having breast cancer, comprising: providing a biological sample comprising breast cancer cells from the patient; contacting said breast cancer cells with an antibody specific for FAM83A; detecting a FAM83A expression level in the breast cancer cells by measuring the level of binding between the antibody and the breast cancer cells; and predicting the clinical outcome of the patient based on the FAM83A expression level, wherein the FAM83A expression level is positively correlated with the breast-cancer related mortality. 2. The method of claim 1 , wherein predicting the clinical outcome comprises generating a Kaplan-Merier survival curve. 3. The method of claim 1 , wherein the antibody specific for FAM83A is a polyclonal antibody against FAM83A. 4. The method of claim 3 , wherein the polyclonal antibody is raised against a peptide having an amino acid sequence of SEQ ID NO: 6. 5. The method of claim 3 , wherein the polyclonal antibody is raised against a peptide having an amino acid sequence of SEQ ID NO: 2. 6. The method of claim 1 , wherein the antibody specific for FAM83A protein is a monoclonal antibody against FAM83A. 7. The method of claim 1 , wherein high expression level of FAM83A in said patient is indicative of high clinical mortality as compared to patients carrying tumors with lower expression levels of FAM83A. 8. The method of claim 1 , wherein the biological sample is a biopsy sample from the patient.
Assignees
Inventors
Classifications
- C07K16/3015Primary
Breast · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9303088B2 cover?
- The application describes therapeutic compositions and methods for treating cancer. For example, therapeutic compositions and methods related to inhibition of FAM83A (family with sequence similarity 83) are provided. The application also describes methods for diagnosing cancer resistance to EGFR inhibitors. For example, a method of diagnosing cancer resistance to EGFR inhibitors by detecting in…
- Who is the assignee on this patent?
- Moonlee Sun-Young, Bissell Mina J, Furuta Saori, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/3015. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).